losartan-potassium has been researched along with Hemoglobinuria* in 5 studies
5 other study(ies) available for losartan-potassium and Hemoglobinuria
Article | Year |
---|---|
Effect of Tumor Necrosis Factor-Alpha on Erythropoietin and Erythropoietin Receptor-Induced Erythroid Progenitor Cell Proliferation in β-Thalassemia/Hemoglobin E Patients.
Thalassemia is one of the genetic diseases that cause anemia and ineffective erythropoiesis. Increased levels of several inflammatory cytokines have been reported in β-thalassemia and might contribute to ineffective erythropoiesis. However, the mechanism by which tumor necrosis factor-alpha (TNF-α) is involved in ineffective erythropoiesis in thalassemic patients remains unclear. The objective of this study is to investigate the effect of TNF-α on the erythropoietin (EPO) and erythropoietin receptor (EPOR) expression involved in proliferation of β-thalassemia/hemoglobin (Hb) E erythroid progenitor cells compared with cells from healthy subjects.. CD34-positive cells were isolated from heparinized blood by using the EasySep® CD34 selection kit. Cells were then cultured with suitable culture medium in various concentrations of EPO for 14 days. The effect of TNF-α on percent cell viability was analyzed by trypan blue staining. In addition, the percentage of apoptosis and levels of EPOR protein were measured by flow cytometry.. Upon EPO treatment, a higher cell number was observed for erythroid progenitor cells from both healthy participants and β-thalassemia/Hb E patients. However, a reduction of apoptosis was found in EPO-treated cells especially for β-thalassemia/Hb E patients. Interestingly, TNF-α caused higher levels of cell apoptosis and lower levels of EPOR protein in thalassemic erythroid progenitor cells.. TNF-α caused a reduction in the level of EPOR protein and EPO-induced erythroid progenitor cell proliferation. It is possible that TNF-α could be involved in the mechanism of ineffective erythropoiesis in β-thalassemia/Hb E patients.. Amaç: Talasemi anemi ve inefektif eritropoeze neden olan genetik hastalıklardan birisidir. Enflamatuvar sitokinlerin bir çoğunun seviyelerinde artma b-talasemide gösterilmiş olup, bu durum inefektif eritropoeze katkıda bulunabilir. Ancak, tümör nekrozlaştırıcı faktör-alfa’nın (TNF-α) talasemik hastalarda inefektif eritropoeze nasıl bir mekanizma ile neden olduğu bilinmemektedir. Bu çalışmanın amacı b-talasemi/hemoglobin (Hb) E eritroid öncül hücrelerinde sağlıklı kontrollerin hücreleri ile karşılaştırıldığında TNF-α’nın eritropoetin (EPO) ve eritropoetin reseptör (EPOR) sunumu üzerine etkisinin araştırılmasıdır. Gereç ve Yöntemler: CD34-pozitif hücreler EasySep® CD34 seçim kiti yardımı ile heparinli kandan izole edildi. Hücreler 14 gün boyunca uygun kültür ortamında değişik EPO konsantrasyonlarında kültürde bekletildi. TNF-α’nın hücre canlılık yüzdesine etkisi tripan mavisi boyası ile incelendi. Bunun yanında, apopitoz yüzdesi ve EPOR protein seviyeleri akış sitometrisi ile ölçüldü. Bulgular: EPO tedavisi ile eritroid öncül hücrelerinin sayısında hem sağlıklı katılımcılarda hem de b-talasemi/Hb E hastalarında artış olduğu görüldü. Ancak özellikle b-talasemi/Hb E hastalarında EPO ile muamele edilmiş hücrelerde apopitozda azalma görüldü. İlginç olarak, TNF-α talasemik eritroid öncül hücrelerde hücre apopitoz oranında artmaya ve EPOR protein seviyelerinde azalmaya neden oldu. Sonuç: TNF-α EPOR protein düzeyi ve EPO ile uyarılmış eritroid öncül hücre çoğalmasında azalmaya neden oldu. b-talasemia/Hb E hastalarında TNF-α inefektif eritropoez mekanizmasında yer alıyor olabilir. Topics: Adult; Apoptosis; beta-Thalassemia; Cell Division; Cells, Cultured; Down-Regulation; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Gene Expression Regulation; Hemoglobin E; Hemoglobinuria; Heterozygote; Humans; Primary Cell Culture; Receptors, Erythropoietin; Tumor Necrosis Factor-alpha; Young Adult | 2015 |
The case/Renal failure after percutaneous closure of a perivalvular leak.
Topics: Acetylcysteine; Aged; Aortic Valve; Aortic Valve Insufficiency; Aspartate Aminotransferases; Bilirubin; Cardiac Catheterization; Drug Administration Schedule; Erythropoietin; Ferrous Compounds; Folic Acid; Glucose; Heart Valve Prosthesis; Hematinics; Hemoglobinuria; Hemolysis; Humans; Infusions, Intravenous; L-Lactate Dehydrogenase; Male; Mitral Valve; Mitral Valve Insufficiency; Renal Insufficiency; Treatment Outcome; Ultrasonography | 2008 |
High-dose erythropoietin for unstable hemoglobin Burke in a patient receiving hemodialysis.
Topics: Aged; Erythropoietin; Hemoglobins, Abnormal; Hemoglobinuria; Humans; Male; Renal Dialysis | 1993 |
The selective inactivation of an ESF-generating factor (EGF) in the presence of erythropoietin (ESF).
Topics: Anemia; Animals; Chromatography, DEAE-Cellulose; Enzyme Inhibitors; Erythropoiesis; Erythropoietin; Hemoglobinuria; Humans; Hydrocarbons, Halogenated; Iron Isotopes; Mice | 1971 |
THE SYNDROME OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.
Topics: Acetylcholinesterase; Alkaline Phosphatase; Anemia; Anemia, Hemolytic; Anticoagulants; Australia; Blood Transfusion; Chromium Isotopes; Coombs Test; Dextrans; Diagnosis, Differential; Drug Therapy; Epoetin Alfa; Erythrocyte Count; Erythrocytes; Erythropoietin; Hematologic Tests; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Hemosiderin; Humans; Iron; Iron Isotopes; Phenindione; Prednisone; Splenectomy; Waldenstrom Macroglobulinemia | 1964 |